The stock of Virax Biolabs Group Ltd (VRAX) has gone down by -14.76% for the week, with a 95.63% rise in the past month and a 50.23% rise in the past quarter. The volatility ratio for the week is 11.49%, and the volatility levels for the past 30 days are 30.80% for VRAX. The simple moving average for the past 20 days is -34.01% for VRAX’s stock, with a 94.07% simple moving average for the past 200 days.
Is It Worth Investing in Virax Biolabs Group Ltd (NASDAQ: VRAX) Right Now?
Company’s 36-month beta value is 2.19.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRAX is 4.05M, and currently, short sellers hold a 15.62% ratio of that floaft. The average trading volume of VRAX on September 16, 2024 was 4.36M shares.
VRAX) stock’s latest price update
Virax Biolabs Group Ltd (NASDAQ: VRAX) has experienced a rise in its stock price by 4.99 compared to its previous closing price of 2.59. However, the company has seen a fall of -14.76% in its stock price over the last five trading days. accesswire.com reported 2024-09-16 that CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ: VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council (“GCC”). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as well as for non-exclusive distribution throughout Europe.
VRAX Trading at 14.78% from the 50-Day Moving Average
After a stumble in the market that brought VRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.79% of loss for the given period.
Volatility was left at 30.80%, however, over the last 30 days, the volatility rate increased by 11.49%, as shares surge +29.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +125.41% upper at present.
During the last 5 trading sessions, VRAX fell by -13.79%, which changed the moving average for the period of 200-days by +25.00% in comparison to the 20-day moving average, which settled at $4.15. In addition, Virax Biolabs Group Ltd saw 86.25% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for VRAX
Current profitability levels for the company are sitting at:
- -39.04 for the present operating margin
- -0.22 for the gross margin
The net margin for Virax Biolabs Group Ltd stands at -43.05. The total capital return value is set at -1.15. Equity return is now at value -92.92, with -88.04 for asset returns.
Based on Virax Biolabs Group Ltd (VRAX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -27.85. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -227.18.
Currently, EBITDA for the company is -6.22 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 54.55. The receivables turnover for the company is 0.72for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.94.
Conclusion
In a nutshell, Virax Biolabs Group Ltd (VRAX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
